Manufacture and sale of medical and quasi-drug products
First written in FY2020-Q2. 5 of 18 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1WorsenedAnnual report
「Sales of products for medical rubber applications declined in the current period as special demand subsided.」
Revenue from medical rubber products declined as special demand subsided. - FY2025MitigatedAnnual report
「For industrial products in Japan, sales of automotive-related products recovered gradually as domestic automobile production recovered, demand for medical rubber products also recovered, and revenue exceeded the same period of the previous year.」
Demand for medical rubber products recovered, and revenue from related products exceeded the same period of the previous year. - FY2025-H1RestatedAnnual report
「For industrial products in Japan, sales of automotive-related products recovered gradually as domestic automobile production recovered, demand for medical rubber products also recovered, and revenue exceeded the same period of the previous year.」
The company continues to report recovery in demand for medical rubber products and higher sales. - FY2024MitigatedAnnual report
「Overseas sales exceeded the previous period due to expanded sales of specialty vulcanizing agents for new applications and recovering demand for products for medical applications.」
Overseas revenue from medical-use products, whose revenue had declined as special demand tapered off and customers adjusted inventories, exceeded the previous period as demand recovered. - FY2024-Q1MitigatedAnnual report
「Demand for medical rubber products recovered gradually, and revenue, led by core products, exceeded the same period of the previous year.」
Demand for medical rubber products, whose revenue had declined as special demand tapered off and customers adjusted inventories, recovered gradually, and revenue exceeded the same period of the previous year. - FY2023RestatedAnnual report
「Revenue from medical rubber products fell below the previous year, partly because of customer inventory adjustments.」
Revenue from medical rubber products fell below the previous period because of the impact of customer inventory adjustments. - FY2023-Q3WorsenedAnnual report
「Medical rubber products were significantly affected by customer inventory adjustments, resulting in lower sales and revenue well below the same period of the previous year.」
Medical rubber products were significantly affected by customer inventory adjustments, resulting in lower sales and revenue well below the same period of the previous year. - FY2023-Q2WorsenedAnnual report
「Medical rubber products were significantly affected by customer inventory adjustments, resulting in lower sales and revenue below the same period of the previous year.」
Medical rubber products were significantly affected by customer inventory adjustments, and sales and revenue fell below the same period of the previous year. - FY2023-Q1RestatedAnnual report
「Special demand for medical rubber products tapered off, resulting in lower sales, and revenue fell below the same period of the previous year.」
Sales and revenue from medical rubber products have continued to decline as special demand tapered off. - FY2022WorsenedAnnual report
「Special demand for the medical rubber products in which the company specializes tapered off, resulting in lower sales. Sales of new products for overseas markets also declined, and revenue fell below the previous period.」
Full-year revenue from medical rubber products fell below the previous period because special demand tapered off and sales of new products for overseas markets declined. - FY2022-Q3Lower revenue from medical rubber products as special demand tapered offAnnual report
「Special demand for medical rubber products tapered off, resulting in lower sales, and revenue fell below the same period of the previous year.」
For medical rubber products, which had increased sales through the previous period, special demand tapered off, and sales and revenue fell below the same period of the previous year. - FY2022-Q2Higher sales of medical rubber products; lower revenue from dehydration-condensation agents for medical applicationsAnnual report
「Medical rubber products with quality and technological advantages increased sales in response to changes in demand.」
Medical rubber products increased sales by responding to changes in demand, while dehydration-condensation agents for medical applications were below the same period of the previous year. - FY2022-Q1Higher sales of medical rubber products; lower revenue from dehydration-condensation agents for medical applicationsAnnual report
「Medical rubber products with quality and technological advantages increased sales in response to higher demand.」
Medical rubber products increased sales in response to higher demand, while dehydration-condensation agents for medical applications were below the same period of the previous year. - FY2021AdvancedAnnual report
「The company increased sales by focusing on medical rubber products with quality and technological advantages.」
Sales increased as the company focused on medical rubber products. - FY2021-Q3AdvancedAnnual report
「The company increased sales by focusing on medical rubber products with quality and technological advantages.」
The company disclosed that it continued to focus on medical rubber products and increased sales. - FY2021-Q2RestatedAnnual report
「The company focused on the manufacture and sale of contract-synthesized products, medical rubber products with quality and technological advantages, and dehydration-condensation agents for medical applications, and worked to expand its market in growth areas.」
The company continues to focus on the manufacture and sale of products with competitive advantages, including medical rubber products and dehydration-condensation agents for medical applications. - FY2020-Q3RestatedAnnual report
「Against this backdrop, the Group addressed demand fluctuations in rapidly deteriorating domestic and overseas markets across the entire company, while focusing on the manufacture and sale of contract-synthesized products, which were seeing rising demand, and medical and pharmaceutical-use products with advantages in quality and technology.」
The company continues to focus on the manufacture and sale of contract-synthesized products and medical and pharmaceutical products, for which demand is increasing. - FY2020-Q2First statedAnnual report
「The company focused on the manufacture and sale of contract-synthesized products for which demand is increasing, as well as medical and pharmaceutical products with strengths in quality and technology.」
The company disclosed for the first time that it was focusing on the manufacture and sale of medical and pharmaceutical products, separately from its existing focus on contract-synthesized products.